Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Short Interest Down 36.8% in July

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 128,849 shares, a decline of 36.8% from the July 15th total of 203,982 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily volume of 43,492 shares, the short-interest ratio is currently 3.0 days.

Key Headlines Impacting Qualigen Therapeutics

Here are the key news stories impacting Qualigen Therapeutics this week:

• Positive Sentiment: Commercial robotics launch: RoboShare completed its first paid commercial order and has an initial fleet of more than 80 robots in place. Management described the transaction as the first market activation under a planned ten-city expansion strategy, providing an early indication of potential revenue-generating operations. AIxC Announces Strategic Pivot to Physical AI and Robotic Operations Commercialization; RoboShare Completes First Paid Commercial Order
• Positive Sentiment: Faraday Future backing: Faraday Future Intelligent Electric (NASDAQ:FFAI), described as AIXC’s majority and controlling shareholder, expressed support for the orderly transition and the company’s focus on Physical AI and robotics commercialization. The backing may improve investor confidence in the new direction and potentially provide strategic resources. Faraday Future Supports AIxC’s Full Strategic Pivot to Physical AI and Robot-Sharing and Rental Operations
• Neutral Sentiment: Frequent LULD pauses: Trading in AIXC was repeatedly halted under Limit Up-Limit Down rules during the session. These pauses signal unusually high volatility and heavy trading interest, but do not by themselves establish a fundamental change in the company’s value.
• Negative Sentiment: Execution and transition risk: AIXC plans to exit its digital asset positions and redirect resources to robotics, meaning the company is abandoning its existing strategy and entering a business with limited disclosed operating history. Investors will likely watch for details on exit costs, financing needs, revenue from the first order, and the ability to scale beyond the initial fleet.

Qualigen Therapeutics Price Performance

AIXC stock traded down $0.06 during trading on Wednesday, reaching $1.26. The company had a trading volume of 3,746,773 shares, compared to its average volume of 503,613. Qualigen Therapeutics has a 52 week low of $0.59 and a 52 week high of $8.81. The business has a 50 day moving average of $1.00 and a 200 day moving average of $1.20. The company has a market cap of $25.60 million, a P/E ratio of -0.22 and a beta of 0.53.

Qualigen Therapeutics (NASDAQ:AIXC) last posted its earnings results on Friday, August 7th. The company reported ($0.21) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Qualigen Therapeutics currently has a consensus rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.